A fatty liver drug from Gilead Sciences posts negative results in late-stage clinical trial
A readout from the first late-stage clinical trial intended to treat the fatty liver disease known as NASH has delivered disappointing results.
Gilead Sciences said Monday that its experimental drug, called selonsertib, failed
